Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Journal Volume
30
Journal Issue
11
Pages
9211
Date Issued
2022-09-03
Author(s)
Abstract
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are frequently associated with dermatologic adverse events (dAEs), having great impacts on patients' health-related quality of life (HRQoL) and treatment adherence. We aimed to examine the association between various dAEs and HRQoL in patients treated with EGFR-TKI therapy.
Subjects
Adverse events; Epidermal growth factor receptor-tyrosine kinase inhibitors; Lung cancer; Osimertinib; Paronychia; Quality of life
SDGs
Publisher
SPRINGER
Type
journal article